Noncompliance leading to drug accumulation resulting in phenytoin toxicity

Journal of the National Medical Association

Volumn 95, Issue 12, 2003, Pages 1201-1203

  Akula, Ravi ^a,b   Hasan, Syed ^a,b   Pipalla, Rao ^a,b   Ferguson, Clifford ^a,b  

^a Center for Sickle Cell Disease ^*

^b HOWARD UNIVERSITY   (United States)

Author keywords

Metabolism; Phenytoin; Toxicity

Indexed keywords

5 (4 HYDROXYPHENYL) 5 PHENYLHYDANTOIN; DICLOFENAC; PHENYTOIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALCOHOL INTOXICATION; ARTICLE; CASE REPORT; DRUG ACCUMULATION; DRUG METABOLISM; DRUG PROTEIN BINDING; GRAND MAL EPILEPSY; HUMAN; HYPOALBUMINEMIA; INJURY; KIDNEY FAILURE; LIVER FAILURE; LIVER METABOLISM; MALE; NEPHROTIC SYNDROME; PATIENT COMPLIANCE; PRIORITY JOURNAL;

ALCOHOLIC INTOXICATION; ANTICONVULSANTS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PATIENT COMPLIANCE; PHENYTOIN;

EID: 0346362497     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Watanabe M, Iwahashi H, Suwahi H, et al. Phenytoin kinetics in Japanese adult epileptics: Phenotype of phenytoin slow metabolizers. Clinical Neuropharmacology. 1997;20:346-351.
2. Arnold K, Gerber N. The rate of decline of diphenylhydantoin in human plasma. Clinical Pharmacol Ther. 1969;11:121-134.
3. Pitner J, Long LD, Meyer RP, et al. Phenytoin toxicity in an older patient with slow metabolism and atypical presentation. Pharmacotherapy. 1998;18:218-225.
4. Kutt H, Haynes J, McDowell. Some causes of ineffectiveness of diphenylhydantoin. Arch Neurolo. 1996;14:489-492.
5. Vasko MR, Bell RD, Daly DD, et al. Inheritance of phenytoin hypometabolism: A kinetic study of one family. Clinical Pharmacol Ther. 1979;27:96-103.
6. Evans DAP, et al. Pharmacogenetics. American Journal of Medicine. 1963;34:639-662.
7. Kutt HI, Wolk M, Scherman R, et al. Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity. Neurology. 1964;14:542-548.
8. Kidd RS, Curry TB, Gallagher S, et al. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 2001;11:803-808.
9. Brandolese R, Scordo MG, Spina E, et al. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clinical Pharmacol Ther. 2001;70:391-394.